Matthew F Sammons

6PUBLICATIONS
52CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsEpigenetics (incl. genome methylation and epigenomics)Molecular targetsInfectious diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.

Jamison B Tuttle, Christophe Allais, Charlotte M N Allerton

|Jan 02, 2025
Design and application of synthetic 17B-HSD13 substrates reveals preserved catalytic activity of protective human variants.

Michelle R Garnsey, Yang Wang, David J Edmonds

|Apr 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner

|Feb 21, 2023
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss.

Michelle R Garnsey, Aaron C Smith, Jana Polivkova

|Nov 02, 2021
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson

|Jan 05, 2018
Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.

David W Piotrowski, Kentaro Futatsugi, Agustin Casimiro-Garcia

Pageof 1